These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14724989)

  • 21. Hyponatremia in heart failure: time for a trial.
    Goldsmith SR
    J Card Fail; 2013 Jun; 19(6):398-400. PubMed ID: 23743488
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
    Goldsmith SR; Elkayam U; Haught WH; Barve A; He W
    J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasopressin antagonists in the management of heart failure.
    Rossi J; Orlandi C; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):323-30. PubMed ID: 17338675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vaptans ante portas: a status report.
    Gross P; Marczewski T; Herbrig K
    Nephrol Dial Transplant; 2009 May; 24(5):1371-3. PubMed ID: 19218537
    [No Abstract]   [Full Text] [Related]  

  • 26. Vasopressin antagonists.
    Lemmens-Gruber R; Kamyar M
    Cell Mol Life Sci; 2006 Aug; 63(15):1766-79. PubMed ID: 16794787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conivaptan (Vaprisol) for hyponatremia.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):51-2. PubMed ID: 16785851
    [No Abstract]   [Full Text] [Related]  

  • 28. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.
    Kinugawa K; Imamura T; Komuro I
    Clin Pharmacol Ther; 2013 Oct; 94(4):449-51. PubMed ID: 23872863
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
    Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
    Acta Neurochir (Wien); 2008 Mar; 150(3):265-71. PubMed ID: 18288441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization.
    De Luca L; Orlandi C; Udelson JE; Fedele F; Gheorghiade M
    Am J Cardiol; 2005 Dec; 96(12A):24L-33L. PubMed ID: 16399090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and in vivo testing of a potential aquaretic agent.
    Kunick C; Link A; Hropot M
    Pharmazie; 1996 Aug; 51(8):601-2. PubMed ID: 8794472
    [No Abstract]   [Full Text] [Related]  

  • 34. [Essential basics in therapy of heart failure. Without diuretics the prognosis is poor].
    Bischoff A
    MMW Fortschr Med; 2002 Jul; 144(29-30):6-8. PubMed ID: 12219622
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of heart failure: a brief review and selected update.
    Unzek S; Francis GS
    Cardiol Clin; 2008 Nov; 26(4):561-71. PubMed ID: 18929231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
    Chen S; Jalandhara N; Batlle D
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):82-95. PubMed ID: 17251996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
    Streefkerk JO; van Zwieten PA
    Auton Autacoid Pharmacol; 2006 Apr; 26(2):141-8. PubMed ID: 16553642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
    Cavalcante JL; Khan S; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.